Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TACE Combined With Sintilimab and Bevacizumab for Unresectable Intermediate and Advanced HCC
NCT04592029Phase 1Completed
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Oct 2020
- Primary completion
- Feb 2023
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Primary endpoints: Adverse Events at 24 months and Progression-Free Survival at 24 months. Started Oct 2020; status: completed.
02
Drugs
sintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04592029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592029.